Research Nester published a report titled Long-acting Beta-agonists Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of the global long-acting beta-agonists market in terms of market segmentation by route of administration, drug type, application, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global long-acting beta-agonists market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2022 – 2031. The market is segmented on the basis of drug type into albuterol, formoterol, salmeterol, and others. Out of these, the formoterol segment is anticipated to hold a substantial share over the forecast period owing to the longer-lasting relief provided from formoterol-based compositions.

Download a Sample Report with Table of Contents and Figures:

The global long-acting beta-agonists market is estimated to grow on the back of increasing prevalence of asthma and other respiratory disorders, along with the higher efficiency of long-acting beta-agonists. Long-acting beta-agonists have a longer effect, which is up to 12 hours, as compared to the 4-5 hour effect of the regular beta-agonists. Moreover, rising adoption of advanced medications and treatment methods is further estimated to boost the market growth.

On the basis of geographical analysis, the global long-acting beta-agonists market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the high incidences of asthma amongst children. As per the data by the Center for Disease Control and Prevention (CDC), 6 million children below 18 years have asthma, in the U.S.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Increasing Prevalence of COPD and Asthma to Fuel the Market Growth

According to the data by the World Health Organization (WHO), 262 million people were diagnosed with asthma in 2019.

The growing cases of asthma and other respiratory diseases, is estimated to boost the market growth. Long-acting beta-agonist is a medication that is capable of relaxing the muscles of the respiratory tract, and prevent asthma attacks for over 12 hours. This drug is ideal for patients with COPD and nocturnal asthma, as they provide relief for longer duration. The growing demand for advanced medical treatment is also anticipated to fuel the market growth.

However, side effects caused by bronchodilators is expected to operate as key restraint to the growth of global long-acting beta-agonists market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global long-acting beta-agonists market which includes company profiling of GlaxoSmithKline plc, Merck KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Sumitomo Dainippon Pharma Co., Ltd., Koninklijke Philips N.V., Pear Therapeutics, Inc., and Sanofi-aventis Groupe. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global long-acting beta-agonists market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future. 

Votes: 0
E-mail me when people leave their comments –

Scott Campbell

You need to be a member of Global Risk Community to add comments!

Join Global Risk Community

    About Us

    The GlobalRisk Community is a thriving community of risk managers and associated service providers. Our purpose is to foster business, networking and educational explorations among members. Our goal is to be the worlds premier Risk forum and contribute to better understanding of the complex world of risk.

    Business Partners

    For companies wanting to create a greater visibility for their products and services among their prospects in the Risk market: Send your business partnership request by filling in the form here!